Hailed as a major scientific advance when they were introduced in the mid-1970s, monoclonal antibodies (mAbs) were slow to be applied outside of the lab. COVID-19 has changed everything.
A rapid development of new and diverse medical indications for mAbs is underway. Ë¿¹ÏÊÓƵAPP's Dr. Daniel D. Zimmerman, Senior Vice President, Head of Global Medical, reviews the clinical indications of monoclonal antibodies, and examines the potential impact of this fast-growing class of therapeutics on insurance medicine. mAbs are also playing an emerging role in the treatment of COVID-19, and this will be addressed.
See also: The Monoclonal Antibody Revolution – What Insurers Need to Know
At Ë¿¹ÏÊÓƵAPP, we are eager to engage with clients to better understand and tackle the industry’s most pressing challenges together. Contact us to discuss and learn more about the Ë¿¹ÏÊÓƵAPP capabilities, resources, and solutions.